Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group

David J. Inwards, Paul A.S. Fishkin, David W. Hillman, David W. Brown, Stephen M. Ansell, Paul J. Kurtin, Rafael Fonseca, Roscoe F. Morton, Michael H. Veeder, Thomas E. Witzig

Research output: Contribution to journal › Article › peer-review

61 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group'. Together they form a unique fingerprint.

Medicine & Life Sciences